The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options

Despite decades of progress, many patients with elevated LDL-C remain above target, underscoring persistent gaps in ASCVD prevention. Prof. Kausik Ray explores why LDL-C control continues to define cardiovascular risk reduction and highlights the expanding therapeutic toolbox—from PCSK9 inhibitors and CETP inhibitors to siRNA and others. As lipid guidelines evolve to incorporate emerging therapies, clinicians must remain current to optimize individualized risk reduction strategies and integrate these novel options into clinical practice.